Literature DB >> 20831903

Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma.

Ju Dong Yang1, W Ray Kim, Ritika Coelho, Teresa A Mettler, Joanne T Benson, Schuyler O Sanderson, Terry M Therneau, Bohyun Kim, Lewis R Roberts.   

Abstract

BACKGROUND & AIMS: There are few data available about the prevalence or effects of cirrhosis in patients with hepatocellular carcinoma (HCC) from viral hepatitis. We compared patients with HCC and hepatitis B virus (HBV) or hepatitis C virus (HCV) infections to determine the proportions of cirrhosis in each group, virologic and tumor characteristics, and overall survival.
METHODS: This analysis included patients with HBV (n = 64) or HCV (n = 118) infection who were diagnosed with HCC at the Mayo Clinic in Rochester, Minnesota from 1994-2008; groups were matched for age and sex. The diagnosis of cirrhosis was based on histology and, if histologic information was insufficient or unavailable, clinical indicators that included ascites or varices, thrombocytopenia or splenomegaly, and radiographic configuration of cirrhosis. Virologic characteristics, tumor stage, and patient survival were also assessed.
RESULTS: The prevalence of histologic cirrhosis was 88% among patients with HBV infection and 93% among those with HCV infection (P = .46). When the most inclusive criteria for cirrhosis were applied, cirrhosis was present in 94% of patients with HBV and 97% with HCV (P = .24). Among HCV patients, 5.2% were negative for HCV RNA after antiviral treatment; 63.4% of HBV patients had HBV DNA <2000 IU/mL with or without treatment. Patients with HBV tended to have less surveillance and more advanced stages of HCC, without differences in survival from those with HCV infection (P = .75).
CONCLUSIONS: Most patients with HCC and chronic viral hepatitis had evidence of cirrhosis, including those with HBV infection and those without active viral replication.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20831903      PMCID: PMC3951426          DOI: 10.1016/j.cgh.2010.08.019

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  31 in total

1.  Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: tumor multicentricity in cirrhotic liver with hepatitis C.

Authors:  S Miyagawa; S Kawasaki; M Makuuchi
Journal:  Hepatology       Date:  1996-08       Impact factor: 17.425

2.  Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.

Authors:  S M Lin; I S Sheen; R N Chien; C M Chu; Y F Liaw
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

3.  Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications.

Authors:  M-F Yuen; H-J Yuan; D K-H Wong; J C-H Yuen; W-M Wong; A O-O Chan; B C-Y Wong; K-C Lai; C-L Lai
Journal:  Gut       Date:  2005-05-04       Impact factor: 23.059

4.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

5.  Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan.

Authors:  Y Shiratori; S Shiina; M Imamura; N Kato; F Kanai; T Okudaira; T Teratani; G Tohgo; N Toda; M Ohashi
Journal:  Hepatology       Date:  1995-10       Impact factor: 17.425

6.  Hepatocellular carcinoma in Italian patients with cirrhosis.

Authors:  M Colombo; R de Franchis; E Del Ninno; A Sangiovanni; C De Fazio; M Tommasini; M F Donato; A Piva; V Di Carlo; N Dioguardi
Journal:  N Engl J Med       Date:  1991-09-05       Impact factor: 91.245

7.  Hepatocellular carcinoma in a hepatitis C patient with sustained viral response and no fibrosis.

Authors:  James H Tabibian; Carmen Landaverde; Julie Winn; Stephen A Geller; Nicholas N Nissen
Journal:  Ann Hepatol       Date:  2009 Jan-Mar       Impact factor: 2.400

8.  Surgical results in patients with hepatitis virus-related hepatocellular carcinoma in Taiwan.

Authors:  Miin-Fu Chen; Long-Bin Jeng; Wei-Chen Lee
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

9.  Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis.

Authors:  Jing Xu; Jian Shi; Yi-Ping Wang; Yong Lin; Yue-Xiang Chen; Jian Lu; Xin Zeng; Wei-Fen Xie
Journal:  Med Sci Monit       Date:  2009-06

10.  Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.

Authors:  Man-Fung Yuen; Wai-Kay Seto; Danny Hoi-Fan Chow; Kit Tsui; Danny Ka-Ho Wong; Vincent Wing-Shun Ngai; Benjamin Chun-Yu Wong; James Fung; John Chi-Hang Yuen; Ching-Lung Lai
Journal:  Antivir Ther       Date:  2007
View more
  81 in total

1.  Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer.

Authors:  M Walker; H B El-Serag; Y Sada; S Mittal; J Ying; Z Duan; P Richardson; J A Davila; F Kanwal
Journal:  Aliment Pharmacol Ther       Date:  2016-01-19       Impact factor: 8.171

2.  Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma.

Authors:  Jung Hee Kim; Dong Hyun Sinn; Kyunga Kim; Wonseok Kang; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik
Journal:  Dig Dis Sci       Date:  2016-07-19       Impact factor: 3.199

3.  Appropriate empirical antibiotic use and 30-d mortality in cirrhotic patients with bacteremia.

Authors:  Hyun Park; Ki Jun Jang; Won Jang; Sang Hoon Park; Ji Young Park; Tae Joo Jeon; Tae Hoon Oh; Won Chang Shin; Won-Choong Choi; Dong Hyun Sinn
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 4.  Epidemiology of viral hepatitis and hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

Review 5.  Chemopreventive strategies in hepatocellular carcinoma.

Authors:  Siddharth Singh; Preet Paul Singh; Lewis R Roberts; William Sanchez
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-08-13       Impact factor: 46.802

6.  Model to estimate survival in ambulatory patients with hepatocellular carcinoma.

Authors:  Ju Dong Yang; W Ray Kim; Kyung Woo Park; Roongruedee Chaiteerakij; Bohyun Kim; Schuyler O Sanderson; Joseph J Larson; Rachel A Pedersen; Terry M Therneau; Gregory J Gores; Lewis R Roberts; Joong-Won Park
Journal:  Hepatology       Date:  2012-07-02       Impact factor: 17.425

7.  Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.

Authors:  Scott M Thompson; Ishan Garg; Eric C Ehman; Shannon P Sheedy; Candice A Bookwalter; Rickey E Carter; Lewis R Roberts; Sudhakar K Venkatesh
Journal:  Br J Radiol       Date:  2018-08-29       Impact factor: 3.039

8.  Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Purva Gopal; Adam C Yopp; Akbar K Waljee; Jason Chiang; Mahendra Nehra; Pragathi Kandunoori; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2013-10-02       Impact factor: 11.382

9.  Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis.

Authors:  Ju Dong Yang; Hager Amed Mohamed; Jessica L Cvinar; Gregory J Gores; Lewis R Roberts; W Ray Kim
Journal:  Am J Gastroenterol       Date:  2016-08-16       Impact factor: 10.864

Review 10.  Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice.

Authors:  Amit G Singal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-15       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.